Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; shows potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM.
More Information Supplier Page
Kobe0065 is a novel and effective small-molecule compound inhibiting Ras–Raf interaction by SBDD; shows potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM.
More Information Supplier Page 
Atglistatin is a highly effective, specific and competitive ATGL inhibitor with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, and no toxicity when the concentration up to 50 μM.
More Information Supplier Page
WH-4-023 is a potent and orally active Lck/Src inhibitor. It also potently inhibits SIK.
More Information Supplier Page
WH-4-023 is a potent and orally active Lck/Src inhibitor. It also potently inhibits SIK.
More Information Supplier Page WH-4-023 is a potent and orally active Lck/Src inhibitor. It also potently inhibits SIK.
More Information Supplier Page 
kb-NB77-78 is an analog of CID797718, which is a by-product of the synthesis of the parental compound, CID755673(PKD1 inhibitor).
More Information Supplier Page
kb-NB77-78 is an analog of CID797718, which is a by-product of the synthesis of the parental compound, CID755673(PKD1 inhibitor).
More Information Supplier Page 
IDO-IN-7 (NLG-919 analogue) is a potent IDO (indoleamine-(2, 3)-dioxygenase) pathway inhibitor.
More Information Supplier Page
IDO-IN-7 (NLG-919 analogue) is a potent IDO (indoleamine-(2, 3)-dioxygenase) pathway inhibitor.
More Information Supplier Page 
